Altered expression of type-1 and type-2 cannabinoid receptors in celiac disease

Natalia Battista; Antonio Di Sabatino; Monia Di Tommaso; Paolo Biancheri; Cinzia Rapino; Paolo Giuffrida; Cinzia Papadia; Chiara Montana; Alessandra Pasini; Alessandro Vanoli; Francesco Lanzarotto; Vincenzo Villanacci; Gino R. Corazza; Mauro Maccarrone

doi:10.1371/journal.pone.0062078

Altered expression of type-1 and type-2 cannabinoid receptors in celiac disease

Natalia Battista, Antonio Di Sabatino, Monia Di Tommaso, Paolo Biancheri, Cinzia Rapino, Paolo Giuffrida, Cinzia Papadia, Chiara Montana, Alessandra Pasini, Alessandro Vanoli, Francesco Lanzarotto, Vincenzo Villanacci, Gino R. Corazza, Mauro Maccarrone

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Anandamide (AEA) is the prominent member of the endocannabinoid family and its biological action is mediated through the binding to both type-1 (CB1) and type-2 (CB2) cannabinoid receptors (CBR). The presence of AEA and CBR in the gastrointestinal tract highlighted their pathophysiological role in several gut diseases, including celiac disease. Here, we aimed to investigate the expression of CBR at transcriptional and translational levels in the duodenal mucosa of untreated celiac patients, celiac patients on a gluten-free diet for at least 12 months and control subjects. Also biopsies from treated celiac patients cultured ex vivo with peptic-tryptic digest of gliadin were investigated. Our data show higher levels of both CB1 and CB2 receptors during active disease and normal CBR levels in treated celiac patients. In conclusion, we demonstrate an up-regulation of CB1 and CB2 mRNA and protein expression, that points to the therapeutic potential of targeting CBR in patients with celiac disease.

Original language	English
Article number	e62078
Journal	PLoS One
Volume	8
Issue number	4
DOIs	https://doi.org/10.1371/journal.pone.0062078
Publication status	Published - 19 Apr 2013

Keywords

Adult
Celiac Disease
Female
Fluorescent Antibody Technique
Gene Expression Regulation
Gliadin
Humans
Intestinal Mucosa
Male
Confocal Microscopy
Protein Binding
Messenger RNA
Cannabinoid Receptor CB1
Cannabinoid Receptor CB2

Access to Document

10.1371/journal.pone.0062078Licence: CC BY

Cite this

@article{066823b10f6f4d2da0aade36a938058e,

title = "Altered expression of type-1 and type-2 cannabinoid receptors in celiac disease",

abstract = "Anandamide (AEA) is the prominent member of the endocannabinoid family and its biological action is mediated through the binding to both type-1 (CB1) and type-2 (CB2) cannabinoid receptors (CBR). The presence of AEA and CBR in the gastrointestinal tract highlighted their pathophysiological role in several gut diseases, including celiac disease. Here, we aimed to investigate the expression of CBR at transcriptional and translational levels in the duodenal mucosa of untreated celiac patients, celiac patients on a gluten-free diet for at least 12 months and control subjects. Also biopsies from treated celiac patients cultured ex vivo with peptic-tryptic digest of gliadin were investigated. Our data show higher levels of both CB1 and CB2 receptors during active disease and normal CBR levels in treated celiac patients. In conclusion, we demonstrate an up-regulation of CB1 and CB2 mRNA and protein expression, that points to the therapeutic potential of targeting CBR in patients with celiac disease.",

keywords = "Adult, Celiac Disease, Female, Fluorescent Antibody Technique, Gene Expression Regulation, Gliadin, Humans, Intestinal Mucosa, Male, Confocal Microscopy, Protein Binding, Messenger RNA, Cannabinoid Receptor CB1 , Cannabinoid Receptor CB2",

author = "Natalia Battista and {Di Sabatino}, Antonio and {Di Tommaso}, Monia and Paolo Biancheri and Cinzia Rapino and Paolo Giuffrida and Cinzia Papadia and Chiara Montana and Alessandra Pasini and Alessandro Vanoli and Francesco Lanzarotto and Vincenzo Villanacci and Corazza, {Gino R.} and Mauro Maccarrone",

note = "{\textcopyright} 2013 Battista et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",

year = "2013",

month = apr,

day = "19",

doi = "10.1371/journal.pone.0062078",

language = "English",

volume = "8",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "4",

}

TY - JOUR

T1 - Altered expression of type-1 and type-2 cannabinoid receptors in celiac disease

AU - Battista, Natalia

AU - Di Sabatino, Antonio

AU - Di Tommaso, Monia

AU - Biancheri, Paolo

AU - Rapino, Cinzia

AU - Giuffrida, Paolo

AU - Papadia, Cinzia

AU - Montana, Chiara

AU - Pasini, Alessandra

AU - Vanoli, Alessandro

AU - Lanzarotto, Francesco

AU - Villanacci, Vincenzo

AU - Corazza, Gino R.

AU - Maccarrone, Mauro

N1 - © 2013 Battista et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2013/4/19

Y1 - 2013/4/19

N2 - Anandamide (AEA) is the prominent member of the endocannabinoid family and its biological action is mediated through the binding to both type-1 (CB1) and type-2 (CB2) cannabinoid receptors (CBR). The presence of AEA and CBR in the gastrointestinal tract highlighted their pathophysiological role in several gut diseases, including celiac disease. Here, we aimed to investigate the expression of CBR at transcriptional and translational levels in the duodenal mucosa of untreated celiac patients, celiac patients on a gluten-free diet for at least 12 months and control subjects. Also biopsies from treated celiac patients cultured ex vivo with peptic-tryptic digest of gliadin were investigated. Our data show higher levels of both CB1 and CB2 receptors during active disease and normal CBR levels in treated celiac patients. In conclusion, we demonstrate an up-regulation of CB1 and CB2 mRNA and protein expression, that points to the therapeutic potential of targeting CBR in patients with celiac disease.

AB - Anandamide (AEA) is the prominent member of the endocannabinoid family and its biological action is mediated through the binding to both type-1 (CB1) and type-2 (CB2) cannabinoid receptors (CBR). The presence of AEA and CBR in the gastrointestinal tract highlighted their pathophysiological role in several gut diseases, including celiac disease. Here, we aimed to investigate the expression of CBR at transcriptional and translational levels in the duodenal mucosa of untreated celiac patients, celiac patients on a gluten-free diet for at least 12 months and control subjects. Also biopsies from treated celiac patients cultured ex vivo with peptic-tryptic digest of gliadin were investigated. Our data show higher levels of both CB1 and CB2 receptors during active disease and normal CBR levels in treated celiac patients. In conclusion, we demonstrate an up-regulation of CB1 and CB2 mRNA and protein expression, that points to the therapeutic potential of targeting CBR in patients with celiac disease.

KW - Adult

KW - Celiac Disease

KW - Female

KW - Fluorescent Antibody Technique

KW - Gene Expression Regulation

KW - Gliadin

KW - Humans

KW - Intestinal Mucosa

KW - Male

KW - Confocal Microscopy

KW - Protein Binding

KW - Messenger RNA

KW - Cannabinoid Receptor CB1

KW - Cannabinoid Receptor CB2

U2 - 10.1371/journal.pone.0062078

DO - 10.1371/journal.pone.0062078

M3 - Article

C2 - 23620805

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e62078

ER -